{"id":"W4390453022","doi":"10.1016/j.jaip.2023.12.043","title":"Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study","year":2023,"lang":"en","type":"article","venue":"The Journal of Allergy and Clinical Immunology In Practice","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sanofi (Canada); University of Toronto","funders":"Mereo BioPharma; Grifols; Canadian Institutes of Health Research; Regeneron Pharmaceuticals; Sanofi; Genentech; AstraZeneca; CSL Behring; GlaxoSmithKline; Amgen","keywords":"Medicine; Adverse effect; Discontinuation; Tolerability; Internal medicine; Asthma; Incidence (geometry); Pediatrics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001375214,0.0005763271,0.001765536,0.0001975526,0.0004219613,0.001031175,0.0005162253,0.000860136,0.001721098],"category_scores_gemma":[0.001309487,0.0002658483,0.00172152,0.000293756,0.0004719077,0.0008006904,0.0003528828,0.002248246,0.0006632414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000678557,"about_ca_system_score_gemma":0.0007395786,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007825221,"about_ca_topic_score_gemma":0.001375412,"domain_scores_codex":[0.9995514,0.000136346,0.00003023071,0.00009510607,0.00008410837,0.0001027597],"domain_scores_gemma":[0.9988248,0.0002052248,0.0002893642,0.0001804427,0.0001416581,0.0003585531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6294485,0.01460384,0.1198436,0.001064449,0.006279294,0.001069842,0.0006500814,0.001119255,0.0320996,0.0003047091,0.00503108,0.1884857],"study_design_scores_gemma":[0.2212069,0.3856759,0.3677932,0.0002449209,0.00627604,0.00176079,0.000397842,0.001951844,0.004053552,0.0003173334,0.0101919,0.0001298249],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965597,0.001676089,0.0001275768,0.0001828262,0.00005232772,0.0001125841,0.0005207385,0.00002280818,0.0007454531],"genre_scores_gemma":[0.9960966,0.000755162,0.0002572029,0.0004086745,0.0001486811,0.000123854,0.001230817,0.000009581709,0.0009695917],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001765536,"threshold_uncertainty_score":0.007272899,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01948275053362067,"score_gpt":0.3372645665778008,"score_spread":0.3177818160441801,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}